CSI Market
Sign In | Register

Viking Therapeutics Inc (VKTX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access VKTX quarterly Cash Flow →
The quarterly cash flow data below helps track how Viking Therapeutics Inc's liquidity profile has evolved over recent quarters.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-359.64
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation40.82
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Change In Fair Value Of Accrued License Fees-
Investment Income Amortization Of Premium-
Amortization Of Financing Costs Equity Transactions0.06
Amortization Of Non Cash Clinical Trial Costs-
Operating Lease Right Of Use Asset Amortization-
Operating Leases Interest Expense0.01
Operating Lease Right Of Use Asset Amortization Expense0.43
Change In Accrued Interest Relating To Marketable Securities Held As Investments-0.51
Income taxes0.00
Realized Investment Gains (Losses), Total-0.06
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable43.44
Increase (Decrease) in Accrued Liabilities6.17
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-5.20
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-4.21
Discontinued operations0.00
Net Cash flow from Operating Activities-278.69
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments341.39
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities341.39
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Increase (Decrease) in Deposits0.00
Other financing activities net0.00
Other net0.00
Proceeds From Stock Issuance Under Employee Stock Purchase Plan And Warrant Exercises-
Proceeds From Warrant And Option Exercises-
Proceeds From Warrant And Option Exercises And Stock Issuance Under Employee Stock Purchase Plan2.49
Payments Of Proceeds From Public Offering And Finance Costs-
Payments Of Proceeds From Public Offering Net Of Offering Costs-
Proceeds From Issuance Of At The Market Equity Offering Sales Agreement Net Of Fees73.95
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities76.44
Effect of exchange rate on cash flow-0.01
Discontinued operations0.00
Free Cash Flow-278.69
Total Cash Flow139.14
4 historic quarters locked

Sign in to unlock the full Viking Therapeutics Inc cash flow history.

Sign In Create Free Account

About Viking Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 11, 2026
  • Source: vktx-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-046876

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License